VCYT
VERACYTE, INC.
NASDAQ · Healthcare · Biotechnology · US
$39.80
−1.91%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $0.43
- Revenue estimate
- $147.2M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- $0.54
- EPS estimate
- $0.41
- Revenue actual
- $150.3M
- Revenue estimate
- $144.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +37.6%
- Revenue beats (12Q)
- 12
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $59
- PT range
- $44 – $69
- Analysts
- 8
6 Buy1 Hold1 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | $0.41 | $0.54 | Beat 31.61% | $150.3M |
| May 5, 2026 | $0.34 | $0.52 | Beat 52.94% | $139.1M |
| Feb 25, 2026 | $0.41 | $0.51 | Beat 23.93% | $140.6M |
| Aug 6, 2025 | $0.31 | $0.44 | Beat 41.94% | $130.2M |
| May 7, 2025 | $0.20 | $0.31 | Beat 55.00% | $114.5M |
| Feb 22, 2024 | -$0.07 | -$0.04 | Beat 42.86% | $98.2M |
| May 4, 2023 | -$0.14 | -$0.11 | Beat 21.43% | $82.4M |
| Feb 22, 2023 | -$0.15 | -$0.05 | Beat 66.67% | $80.3M |
| Nov 2, 2022 | -$0.24 | -$0.12 | Beat 50.00% | $75.6M |
| Aug 2, 2022 | -$0.21 | -$0.13 | Beat 38.10% | $72.9M |
| May 3, 2022 | -$0.23 | -$0.20 | Beat 13.04% | $67.8M |
| Feb 28, 2022 | -$0.14 | -$0.15 | Miss -7.14% | $67.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026